English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 April 2019, 04:00 HKT/SGT
Share:
    

Source: Novotech
Novotech CRO strengthens South Korean Clinical Capabilities, partners with 2 Major Hospitals
Ulsan University Hospital (UHH) and Seoul National University Hospital (SNUH), Hepatology Division have joined the Novotech CRO partnership program

SYDNEY, Apr 18, 2019 - (ACN Newswire) - Novotech, the award-winning Asia-Pacific CRO with 23 years of experience in the region, has further strengthened its presence in South Korea with two major hospitals joining the Novotech partnership program - bringing more quality investigators, KOLs, and up to 4 million patients.

The 900 bed Ulsan University Hospital (UUH), and the Hepatology Division in Gastroenterology, Department of Internal Medicine at the 1,778 bed Seoul National University Hospital (SNUH), have joined the Novotech CRO partnership program, further strengthening Novotech's clinical service capabilities in South Korea.

South Korea is a fast-growing destination for clinical studies with quality infrastructure, world-class medical and hospital facilities, and supportive rapid start-up regulations. South Korea was Asia's most active country in clinical research after China last year, with over 400 sites opened by biopharma companies.

Novotech is well established in Asia with offices in 11 countries and more than 550 staff, while 19 leading hospitals and medical facilities across the region have now joined the Novotech CRO clinical partnership program.

Novotech CEO Dr John Moller said biotech clients were increasingly running Phase I studies in Australia, benefiting from the 41% R&D tax credit, then moving to Asia for subsequent trials. "Having the same company that understands the study as it transitions into Asia is always reassuring for clients. Novotech uses the latest Oracle and Medidata technology, so seamlessly connects with global clinical partners."

About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials across the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.

For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0

Media Contact:
[email protected]
Susan Fitzpatrick-Napier, AU: +61 2 8218 2144
USA: +1 415 951 3228, Asia: +65 3159 3427

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Novotech Releated News
July 11, 2019 11:00 HKT/SGT
Novotech CRO partners Skin Research Institute of Singapore (SRIS) for Skin Disorder Research
May 31, 2019 07:00 HKT/SGT
Novotech Awarded Asia-Pacific Biotech CRO of the Year - Announced at ASCO
May 31, 2019 07:00 HKT/SGT
노보텍, ASCO에서 올해의 아시아태평양 생명과학 CRO상 수상
Apr 19, 2019 07:00 HKT/SGT
노보텍, 서울대병원 소화기내과 간파트와 업무 협약 체결
Mar 25, 2019 18:00 HKT/SGT
Novotech CNS USA Appoints Dr Robert Malone to its Washington, DC BioDesk
More news >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575